Ophthalmic Drug Delivery Systems - part 7 docx

tropicamide liposomes (63). Both polymer coatings of tropicamide-containing liposomes failed to significantly increase the bioavailability of the entrapped drug relative to uncoated vesicles (63). However, in contrast to previous work (53), size and zeta potential measurements of uncoated tropicamide liposomes and liposomes coated in both polymer solutions demonstrated an association between the Carbopols and the vesicles at both pH 7.4 and pH 5, as evidenced by an increase in size and a decrease in the corresponding zeta potential. It was suggested that the prolongation in precorneal residence for Carbopol 1342–coated tropicamide liposomes was due to the formation of a three-dimensional microgel structure, which interacted with the phospholipid vesicles and subsequently increased their retention via a mechanism of adhesion to the mucin network (63). Microsphere formulations have been evaluated for their capacity to retain 111 In as indium chloride in the preocular (precorneal) area of the rabbit eye (64). Clearance of the radiolabeled compound was monitored using gamma scintigraphy, and the influence of pH and prehydration of the microspheres on precorneal retention was assessed. These authors pre- pared microspheres of poly(acrylic acid) (Carbopol 907) cross-linked with maltose by a water-in-oil (w/o) emulsification process. Precorneal clearance of the microspheres at pH 5 and 7.4 were compared to an 111 In aqueous suspension (64). Clearance of the microspheres demonstrated a biphasic ( ¼ rapid initial phase and  ¼ slower phase) profile, and microspheres buffered at pH 5 exhibited a significantly slower  phase than micr ospheres buffered at pH 7.4. Presumably, the neutralized Carbopol formulation (pH 7.4) did not possess the same degree of mucoadhesive strength as the microsphere preparation formulated at pH 5. In vitro tests of mucoadhesive strength verified that the force of detachment of the microspheres formulated at pH 5 from mucus glycoprotein was significantly greater than the corresponding value for microspheres buffered at pH 7.4 (64). A significant increase in the retention of prehydrated microspheres in the preocular area was observed compared to microsphere formulations that were not hydrated prior to instillation (64). Albasini and Ludwig (65) evaluated a series of polysaccharides for their potential inclusion in ocular dosage forms. The polysaccharides evaluated were carrageenan, locust bean gum, guar gum, xanthan gum, and scleroglucan. Measurements of the dynamic surface tension, pH, refractive index, and a visual clarity check comprised the physical measurements and determination of viscosity, viscoelasticity, effect of ionic strength on the resulting viscosity, and mucoadhesive strength (as assessed by an increase in the viscosity of a solution of the polysaccharide and mucin) comprised the rheological analysis of all the polysaccharides evaluated (65). All ocular preparations were made by adding the required amount of each polysac- 426 Johnston et al. Copyright © 2003 Marcel Dekker, Inc. charide to an aqueous iso-osmotic vehicle at 90  C and stirring the mixture mechanically until the polysaccharide was completely dissolved (65). Only scleroglucan and xanthan gum were found to demonstrate desirable viscoe- lastic and mucoadhesive properties suitable for instillation into the eye. The two preparations were evaluated in human volunteers and found to possess no ocular irritancy (65). Polysaccharides have also been shown to have potential for drug delivery by other routes of administration. Using a high molecular weight polysaccharide gum, Hakea gibbosa, isolated from a tree, Alur et al. have shown that the gum possessed both the ability to sustain the release of low molecular weight, organic-based drug substances as well as therapeutic polypeptides (salmon calcitonin) both in vitro and in vivo following application to the buccal mucosa of rabbits (74–76). This polysaccharide may hold promise for sustained delivery to the eye of both conventional drugs and newer therapeutic polypeptides requiring retention of biological activity. The biomaterials for ocular use have been mainly synthetic polymers. Some natural biopolymers, such as collagen and hyaluronic acid, have also been examined. Of these, hyaluronic acid offers attractive possibilities (77– 80). Some of the materials indicated as ‘‘ocular mucoadhesives’’ are men- tioned below. A. Naturally Occurring Mucoadhesives Collagen and fibrin have been used as erodible insets for the long-term delivery of pilocarpine to the eye (81,82). The utility of these macromole- cules in ophthalmic drug delivery depends largely upon their attachment capability to the drug molecules and their interaction with the glycocalyx domain of the corneal surface for maximum mucoadhesion. Among these, lectins and fibronectin are most promising. The role of lectins as cellular-recognition mediators has been explored in great detail in the field of cellular biology. Lectins belong to a class of proteins of nonimmune origin that bind carbohydrates specifically and non- covalently (83). The most commonly studied lectin is the one derived from tomatoes. This particular lectin has been found to be nontoxic, binds specifically to the sialic acids (a major component of the mucus glycoproteins), and is transported into the cells by endocytosis (84). Such properties could be useful for the delivery of therapeutic agents into the ocular chambers. Fibronectin is a glycoprotein and a component of the extracellular matrix. The pentapeptide backbone of this substance has been identified as having a cell-attachment property (85). Purified fibronectin has been reported to lessen the healing time of corneal ulcers (86). It has also been used in conjunction with hyaluronic acid for decreasing the healing time. Mucoadhesive Polymers in Ophthalmic Drug Delivery 427 Copyright © 2003 Marcel Dekker, Inc. B. Synthetic Mucoadhesives As discussed earlier, the potential of a mucoadhesive agent is determined by a number of parameters; i.e., chain length, configuration, and molecular weight. The extent of corneal adhesion of some neutral polymers has been reported to be comparable to that of natural mucins. Lemp and Szymanski (87) measured the extent of corneal adsorption of water-soluble polymers onto the epithelial surface. Among the polymers, 1.4% polyvinyl alcohol, 0.5% hydroxypropyl methyl cellulose, and 2% hydroxyethyl cellulose vehicles have shown comparable corneal adhesion to that of mucin. The study concluded that ocular therapeutic agents would be well absorbed from topical formulations containing such polymers. Since only marginal improve- ments (two- to threefold) in ocular bioavailability were seen with these agents, the adsorbed polymers were either unable to hold the drug or were being rapidly removed from the surface by the bathing tears. Other water-soluble polymers like polyacrylic acid also improved the ocular bioavailability of pilocarpine, albeit by a factor of two. A polymer most effective as a mucoadhesive will be the one that can form an extended and hydrated network to allow for greater interpenetra- tion and subsequent physical entanglement. These kinds of networks may be formed by: 1. Physical intertwining of the polymers 2. Bridging of the polymer chains 3. Cross-linking of the polymer chains Thus, cross-linked polyacrylic acid has been shown to have an excel- lent mucoadhesive property, causing significant enhancement in ocular bioavailability (55). Using pigmented rabbits, Lehr et al. (88) demonstrated a twofold increase in the uptake of gentamicin by the bulbar conjunctiva when the aminoglycoside was delivered as a mucoadhesive, polycarbophil [a poly(acrylic acid)–based polymer] formulation. Two gentamicin formulations of this polymer (neutralized vs. nonneutralized) were evaluated and compared to an aqueous control formulation. While both the neutralized (pH 7.5) and nonneutralized (pH 2.5) gentamicin/polycarbophil formulations increased the uptake of the aminoglycoside antibiotic by the bulbar conjunctiva, only the nonneutralized aminoglycoside formulation provided drug penetration into the aqueous humor. Penetration of gentamicin into the aqueous humor from the nonneutralized formulation was suggested to result from drug absorption via the conjunctival-scleral pathway facilitated by intensified contact between the mucoadhesive polymer and the under- lying bulbar conjunctiva (88). A partially esterified acrylic acid polymer was successful in prolonging the therapeutic effect of topically applied pilocar- 428 Johnston et al. Copyright © 2003 Marcel Dekker, Inc. pine (89). Urtti et al. (90) also indicated that the use of a polyacrylamide and a copolymer of acrylamide (N-vinyl pyrrolidone and ethyl acrylate) as a matrix, which resulted in a threefold increase in the ocular bioavailability of pilocarpine. Similarly, cyanoacrylates have been used in the field of opthalmology to seal corneal perforations and ulcers, to stop leakage of aqueous or vitreous humor, and to protect against external contamination (91,92). These agents have a potential as effective ocular mucoadhesive agents provided the monomer polymerization could be controlled. III. WHAT IS IN STORE FOR THE FUTURE? A multidisciplinary approach will be necessary to overcome the challenges associated with the development of ocular mucoadhesives. A nonbiodegrad- able adhesive is adequate for topical use to treat perforations and ulcera- tions. However, the use of a nontoxic biodegradable surgical adhesive is deemed necessary for long-term use in ocular drug delivery. Mucoadhesives can make an important contribution in this area. An ideal ocular mucoadhesive would be site specific, durable for the desired period of time, biodegradable, and above all nontoxic, nonimmunogenic, and nonir- ritant. It would be even better if the adhesive could serve as absorption enhancers (for therapeutic protein and peptide drugs) and/or as enzyme inhibitors. REFERENCES 1. Harris, D., and Robinson, J. R. (1990). Bioadhesive polymers in peptide drug delivery, Biomaterials, 11:652. 2. Schacter, H., and Williams, D. (1982). Biosynthesis of mucus glycoproteins, Adv. Exp. Med. Biol., 144:3. 3. Marriot, C., and Gregory, N. P. (1990). Mucus physiology and pathology. In: Bioadhesive Drug Delivery Systems (V. Lenaerts and R. Gurny, eds.). CRC Press, Boca Raton, FL, p. 21. 4. Allen, A. (1981). The structure and function of gastrointestinal mucus. In: Basic Mechanisms of Gastrointestinal Mucosal Cell Injury and Protection (J. W. Harmon, ed.). Williams & Wilkins, Baltimore, p. 351. 5. Allen, A., and Carrol, N. J. H. (1985). Adherent and soluble mucus in the stomach and duodenum, Dig. Dis. Sci., 30:55s. 6. Gandhi, R. B., and Robinson, J. R. (1988). Bioadhesion in drug delivery, Indian J. Pharm. Sci., 50:145. Mucoadhesive Polymers in Ophthalmic Drug Delivery 429 Copyright © 2003 Marcel Dekker, Inc. 7. Marriot, C., and Hughes, D. R. L. (1989). Mucus physiology and pathology. In: Bioadhesion: Possibilities and Future Trends (R. Gurny and H. E. Junginger, eds.). Wissenschaftliche Verlagsgesellschaft, Stuttgart, p. 29. 8. Johnson, P. M., and Rainsford, K. D. (1978). The physical properties of mucus: Preliminary observations on the sedimentation behavior of porcine gastric mucus, Biochim. Biophys. Acta, 286:72. 9. Phelps, C. F. (1978). Biosynthesis of mucus glycoproteins, Br. Med. Bull., 34:43. 10. Robinson, J. R. (1989). Ocular drug delivery. Mechanism(s) of corneal drug transport and mucoadhesive delivery systems, S.T.P. Pharma, 5:839. 11. Mikos, A. G., and Peppas, N. A. (1986). Systems for controlled release of drug. V. Bioadhesive systems, S.T.P. Pharm., 2:705. 12. Dedaguin, B. V., Toporov, Y. P., Mueler, V. M., and Aleinikova, I. N. (1977). On the relationship between the electrostatic and the molecular component of the adhesion of elastic particles to a solid surface. J. Colloid Interface Sci., 58:528. 13. Baier, R.E., Shafrin, I.G., and Zisman, W.A. (1968). Adhesion: Mechanism that assist and impede it, Science, 162:1360. 14. Helfand, E., and Tagami, Y. (1971). Theory of the interface between immis- cible polymers, Polym. Lett., 9:741. 15. Helfand, E., and Tagami, Y. (1972). Theory of the interface between immis- cible polymers. II. J. Chem. Phys., 56:3592. 16. Helfand, E., and Tagami, Y. (1972). Theory of the interface between immis- cible polymers, J. Chem. Phys., 57:1812. 17. Peppas, N. A., and Buri, P. A. (1985). Surface, interfacial and molecular aspects of polymer adhesion on soft tissues, J. Controlled Release, 2:257. 18. Peppas, N. A., and Lustig, B. R. (1985). The role of crosslinks, entanglements, and relaxations of the macromolecular carrier in the diffusional release of biologically active materials: Conceptual and scaling relationships, Ann. NY Acad. Sci., 446:26. 19. Reinhart, C. T., and Peppas, N. A. (1984). Solute diffusion in swollen mem- branes. II. Influence of crosslinking on diffusive properties. J. Membr. Sci., 18:227. 20. Peppas, N. A., and Reinhart, C. T. (1983). Solute diffusion in swollen mem- branes. Part I. New therapy, J. Membr. Sci., 15:275. 21. Tabor, D. J. (1977). Surface forces and surface interactions, J. Colloid Interface Sci., 58:2. 22. Kinloch, A. J. (1980). The science of adhesion: I. Surface and interfacial aspects, J. Mater. Sci., 15:2141. 23. Good, R. J. (1977). Surface free energy of solids and liquids: Thermodynamics, molecular forces and structure, J. Colloid Interface Sci., 58:398. 24. Ponchel, G., Touchard, F., Duchene, D., and Peppas, N. A. (1987). Bioadhesive analysis of controlled release systems. I. Fracture and interpene- 430 Johnston et al. Copyright © 2003 Marcel Dekker, Inc. tration analysis in poly(acrylic acid) containing systems, J. Controlled Release, 5:129. 25. Mikos, A. G., and Peppas, N. A. (1988). Polymer chain entanglements and brittle fracture, J. Chem. Phys., 88:1337. 26. Wake, W. C. (1976). Theories of adhesion and adhesive action. In: Adhesion and Formulation of Adhesives. Applied Science, London, p. 65. 27. Israelachvili, J. N. (1985). Intermolecular and Surface Forces. Academic Press, New York. 28. Pritchard, W. H. (1971). The role of hydrogen bonding in adhesion, Aspects Adhes., 6:11. 29. Colo, G. D., Bugalassi, S., Chetoni, P., Fiaschi, M. P., Zambito, Y. and Sattone, M. F. (2001). Relevance of polymer molecular weight to the in vitro/in vivo performances of ocular inserts based on poly(ethylene oxide), Int. J. Pharmaceutics, 220:169. 30. Park, H., and Robinson, J. R. (1985). Physico-chemical properties of water insoluble polymers important to mucin/epithelial adhesion, J. Controlled Release, 2:47. 31. Nagai, T., and Machida, Y. (1985). Advances in drug delivery. Mucosal adhesive dosage forms, Pharma. Int. Engl. Ed., August:196. 32. Satoh, K., Takayama, K., Machida, Y., Suzuki, Y., Nakagaki, M., and Nagai, T. (1989). Factors affecting the bioadhesive properties of tablets con- sisting of hydroxypropyl cellulose and carboxy vinyl polymers, Chem. Pharm. Bull., 37:1366. 33. Gottschalk, A. (1960). In: The Chemistry and Biology of Sialic Acid and Related Substances. Cambridge University Press, London. 34. Leonard, F., Hodge, J. W., Jr., Houston, S., and Ousterhout, D. K. (1968). Alpha cyanoacrylate adhesive bond strengths with proteinaceous and non proteinaceous substances, J. Biomed. Mater. Res., 2:173. 35. Smart, J. D., Kellaway, I. W., and Worthington, H. E. C. (1984). An in vitro investigation of mucosal adhesive materials for use in controlled drug delivery, J. Pharm. Pharmacol., 36:295. 36. Leung, S. H. S., and Robinson, J. R. (1990). Polymer structure features con- tributing to mucoadhesion. II., J. Controlled Release, 12:187. 37. Chen, J. L., and Cyr, G. N. (1970). Compositions producing adhesion through adhesion. In: Adhesive Biological Systems (R. S. Manly, ed.). Academic Press, New York, p. 78. 38. Smart, J. D. (1991). An in vitro assessment of some muco-adhesive dosage forms, Int. J. Pharm., 73:69. 39. Park, K., and Park, H. (1990). Test methods of bioadhesion. In: Bioadhesive Drug Delivery Systems (V. Lenaerts and R. Gurny, eds.). CRC Press, Boca Raton, FL, p. 43. 40. Wang, P. Y., and Forrester, D. H. (1974). Conditions for the induced adhesion of hydrophobic polymers to soft tissue, Trans. Am. Soc. Artif. Int. Organs, 20:504. Mucoadhesive Polymers in Ophthalmic Drug Delivery 431 Copyright © 2003 Marcel Dekker, Inc. 41. Teng, C. L. C., and Ho, N. F. L. (1987). Mechanistic studies in the simulta- neous flow and adsorption of polymer coated latex particles on intestinal mucus. I: Methods and physical model development, J. Controlled Release, 6:133. 42. Zaki, I., Fitzgerald, P., Hardy, J. G., and Wilson, C. G. (1986). A comparison of the effect of viscosity in the precorneal residence of solutions in rabbit and man, J. Pharm. Pharmacol., 38:463. 43. Moss, R. A. (1987). The eyelids. In: Adler’s Physiology of the Eye: Clinical Applications, 8th ed. (R. A. Moses and W. M. Hart, Jr., eds.). Mosby, St. Louis, p. 1. 44. Saettone, M. F., Giannaccinni, B., Guiducci, A., LaMarca, F., and Tota, G. (1985). Polymer effects on ocular bioavailability. II: The influence of benzalk- onium chloride on the mydriatic response of tropicamide in different polymeric vehicles, Int. J. Pharm., 25:73. 45. Wright, P., and Mackie, I. A. (1977). Mucus in healthy and diseased eye, Trans. Ophthalmol. Soc. UK, 91:1. 46. Hardy, J. G., Lee, S. W., and Wilson, C. G. (1985). Intranasal drug delivery by sprays and drops, J. Pharm. Pharmacol., 37:294. 47. Tabachnik, N. F., Blackburn, P., and Cerami, A. (1981). Biochemical and rheological characteristics of sputum mucus from a patients with cystic fibro- sis, J. Biol. Chem., 256:7161. 48. Swan, K. C. (1945). Use of methylcellulose in ophthalmology, Arch. Ophthalmol., 33:378. 49. Mueller, W. H., and Deardorff, D. L. (1956). Ophthalmic vehicles: The effect of methylcellulose on the penetration of Homatropine hydrobromide through the cornea, J. Am. Pharm. Assoc., 45:334. 50. Oechsner, M., and Keipert, S. (1999). Polyacrylic acid/polyvinylpyrrolidone biopolymeric systems. I. Rheological and mucoadhesive properties of formulations potentially useful for the treatment of dry-eye syndrome, Eur. J. Pharm. Biopharm., 47:113–118. 51. Saettone, M. F., Giannaccinni, B., Ravecca, S., La Marca, F., and Tota, G. (1984). Polymer effects of ocular bioavailability: The influence of different liquid vehicles on the mydriatic response of tropicamide in humans and in rabbits, Int. J. Pharm., 20:187. 52. Benedetto, D. A., Shah, D. O., and Kaufman, H. E. (1975). Instilled fluid dynamics and surface chemistry of polymers in the preocular tear film, Invest. Ophthalmol., 14:887. 53. Davies, N. M., Farr, S. J., Hadgraft, J., and Kellaway, I. W. (1991). Evaluation of mucoadhesive polymers in ocular drug delivery. I. Viscous solutions, Pharm. Res., 8:1039–1043. 54. Huupponen, R., Kaila, T., Saettone, M. F., Monti, D., Iisalo, E., Salminen, L., and Oksala, O. (1992). The effect of some macromolecular ionic complexes on the pharmacokinetics and dynamics of ocular cyclopentolate in rabbits, J. Ocular Pharmacol., 8:59–67. 432 Johnston et al. Copyright © 2003 Marcel Dekker, Inc. 55. Hui, H. W., and Robinson, J. R. (1985). Ocular delivery of progesterone using a bioadhesive polymer, Int. J. Pharm., 26:203. 56. Saettone, M. F., Chetoni, P., Torracca, M. T., Burgalassi, S., and Giannaccinni, B. (1989). Evaluation of mucoadhesive properties and in vivo activity of ophthalmic vehicles based on hyaluronic acid, Int. J. Pharm., 51:203. 57. Saettone, M. F., Giannaccini, B., Chetoni, P., Galli, G., and Chiellini, E. (1984). Vehicle effects on the ophthalmic bioavailability: An evaluation of polymeric inserts containing pilocarpine, J. Pharm. Pharmacol., 36:229. 58. Chetoni, P., Di Colo, G., Grandi, M., Morelli, M., Saettone, M. F., and Darougar, S. (1998). Silicone rubber/hydrogel composite ophthalmic inserts: Preparation and preliminary in vitro/in vivo evaluation, Eur. J. Pharm. Biopharm., 46:125–132. 59. Finne, U., Salivirta, J., and Urtti, A. (1991). Sodium acetate improves the ocular/systemic absorption ratio of timolol applied ocularly in monoisopropyl PVM-MA matrices, Int. J. Pharm., 75:R1. 60. Losa, C., Calvo, P., Castro, E., Vila-Jato, J. L., and Alono, M. J. (1991). Improvement of ocular penetration of amikacin sulphate by association to poly(butylcyanoacrylate) nanoparticles, J. Pharm. Pharmacol., 43:548. 61. Vanderhoff, J., El-Asser, E. R., and Urgerstad, J. (1977). U.S. Patent Application #867031. 62. Kumar, S., Haglund, B. O., and Himmelstein, K. J. (1994). In situ-forming gels for opthalmic drug delivery, J. Ocular Pharmacol. 10:47. 63. Davies, N. M., Farr, S. J., Hadgraft, J., and Kellaway, I. W. (1992). Evaluation of mucoadhesive polymers in ocular drug delivery. II. Polymer- coated vesicles, Pharm. Res., 9:1137–1144. 64. Durrani, A. M., Farr, S. J., and Kellaway, I. W. (1995). Precorneal clearance of mucoadhesive microspheres from the rabbit eye, J. Pharm. Pharmacol., 47:581–584. 65. Albasini, M., and Ludwig, A. (1995). Evaluation of polysaccharides intended for ophthalmic use in ocular dosage forms, Farmaco, 50:633–642. 66. Lee, V. H. L., Li, S. Y., Sasaki, H., Saettone, M. F., and Chetoni, P. (1994). Influence of drug release rate on systemic timolol adsorption from polymeric occular inserts in the pigmented rabbit, J. Ocular. Pharmacol., 10:421–429. 67. Das, S. K., Tucker, I. G., Hill, D. J. T., and Ganguly, N. (1995). Evaluation of poly(isobutylcyanoacrylate) nanoparticles for mucoadhesive ocular drug delivery. I. Effect of formulation variables on physicochemical characteristics of nanoparticles, Pharm. Res., 12:534–540. 68. Robinson, J. R., and Li, V. H. K. (1984). Ocular disposition and bioavailability of pilocarpine from Piloplex 1 and other sustained release drug delivery systems. In: Recent Advances in Glaucoma (U. Ticho and R. David, eds.). Excerpta Medica, Amsterdam, p. 231. 69. Saettone, M. F., Giannaccinni, B., Guidicci, A., and Savigni, P. (1986). Semisolids ophthalmic vehicles. III. An evaluation of four organic hydrogels containing pilocarpine, Int. J. Pharm., 31:261. Mucoadhesive Polymers in Ophthalmic Drug Delivery 433 Copyright © 2003 Marcel Dekker, Inc. 70. Joshi, A., Ding, S., and Himmelstein, K. J. Patent application U.S. 91/04104 (Publication No. WO 91/19481). 71. Kumar, S., and Himmelstein, K. J. (1995). Modification of in situ gelling behavior of carbopol solutions by hydroxypropyl methylcellulose. J. Pharm. Sci., 84:344. 72. Rozier, A., Mazuel, C., Grove, J., and Plazonnet, B. (1989). Gelrite: a novel, ion activated, in situ gelling polymer for ophthalmic vehicles. Effect on bioavailability of timolol, Int. J. Pharmaceutics, 57:163. 73. Sanzigiri, Y. D., Maschi, S., Crescenzi, V., Callegaro, L., Topp, E. M., and Stella, V. J. (1993). Gellan-based systems for ophthalmic sustained delivery of methylprednisolone. J. Control Release, 26:195. 74. Alur, H. H., Pather, S. I., Mitra, A. K., and Johnston, T. P. (1999). Transmucosal delivery of chlorpheniramine maleate from a buccal tablet containing a natural, mucoadhesive gum, Int. J. Pharm., 188:1–10. 75. Alur, H. H., Beal, J. D., Panther, S. I., Mitra, A. K., and Johnston, T. P. (1999). Evaluation of a novel, natural oligosaccharide gum as a sustained- release and mucoadhesive component of calcitonin buccal tablets, J. Pharm. Sci., 88:1313–1319. 76. Alur, H. H., Pather, S. I., Mitra, A. K., and Johnston, T. P. (1999). Evaluation of the gum Hakea gibbosa as a sustained-release and mucoadhesive component in buccal tablets, Pharm. Develop. Technol., 4:347–358. 77. Benditti, L. M., Kyyronen, K., Hume, L., Topp, E., and Stella, V. (1991). Steroid ester of hyaluronic acid in ophthalmic drug delivery, Proc. Int. Symp. Controlled Release Bioact. Mater., 18:497. 78. Saettone, M. F., Giannaccinni, B., Torracca, M. T., and Burgalassi, S. (1987). An evaluation of the bioadhesive properties of hyaluronic acid. Proceedings of the 3rd Eur. Congress on Biopharm. Pharmacokinetics, Vol. 1, Freiburg, April, p. 413. 79. Saettone, M. F., Chetoni, P., Torracca, M. T., Giannaccinni, B., and Ordello, G. (1986). Evaluation of hyaluronic acid as a vehicle for topical ophthalmic drugs. Abstr. of Int. Symp. Ophthalmic Dosage Forms, Pisa, Oct. 13–14. 80. Saettone, M. F., Chetoni, P., and Giannaccinni, B. (1985). Evaluation of hyaluronic acid as a vehicle for topical ophthalmic drugs, Abstr. of 2nd Int. Conference on Polymers in Medicine, Capri, June 3–7. 81. Miyazaki, S., Ishii, K., and Takada, M. (1982). Use of fibrin film as a carrier for drug delivery: A long acting delivery system for pilocarpine into the eye. Chem. Pharm. Bull., 30:3405. 82. Bloomfield, S. E., Miyata, T., Dunn, M. W., Bueser, N., Stenzel, K. H., and Rubin, A. L. (1978). Soluble gentamicin ophthalmic inserts as a drug delivery system, Arch. Ophthalmol., 96:885. 83. McCoy, J. P., Jr. (1986). Contemporary laboratory applications of lectins, Biotechniques, 4:252. 84. Kilpatrick, D. C., Pusztai, A., Grant, G., Graham, G., and Ewen, S. W. B. (1985). Tomato lectins resist degradation in the mammalian alimentary canal and binds to intestinal villi without deleterious effects, FEBS Lett., 185:299. 434 Johnston et al. Copyright © 2003 Marcel Dekker, Inc. 85. Hynes, R. O., and Yamada, K. M. (1982). Fibronectins: Multifunctional modular glycoproteins, J. Cell Biol., 95:369. 86. Nishida, T., Ohashi, Y., Awanta, T., and Manabe, R. (1983). Fibronectin, new therapy for corneal trophic ulcer, Arch. Ophthalmol., 101:1046. 87. Lemp, M. H., and Szymanski, E. S. (1975). Polymer adsorption at the ocular surface, Arch. Ophthalmol., 99:134. 88. Lehr, C. M., Lee, Y. H., and Lee, V. H. L. (1994). Improved ocular penetration of gentamicin by mucoadhesive polymer polycarbophil in the pigmented rabbit, Invest. Ophthalmol. Vis. Sci., 35:2809–2814. 89. Ticho, U., Blumenthal, M., Zonis, S., Gal, A., Blank, L., Mazor, Z. W. (1979). A clinical trial with Piloplex 1 —a new long-acting pilocarpine compound: Preliminary report, Ann. Ophthalmol., April:555. 90. Urtti, A., Salminen, L., Kujari, H., and Jantti, V. (1984). Effect of ocular pigmentation on pilocarpine pharmacology in the rabbit eye. II. Drug response, Int. J. Pharm., 19:53. 91. Refojo, M. F. (1982). Current status of biomaterials in ophthalmology, Surv. Ophthalmol., 26:257. 92. Refojo, M. F., Dohlman, C. H., and Koliopoulos, J. (1971). Adhesives in ophthalmology: A review, Surv. Ophthalmol., 15:217. Mucoadhesive Polymers in Ophthalmic Drug Delivery 435 Copyright © 2003 Marcel Dekker, Inc. [...]... favorable characteristic for a preferred pharmaceutical drug delivery system Copyright © 2003 Marcel Dekker, Inc Microparticles and Nanoparticles in Ocular Drug Delivery II PARTICULATE SYSTEMS IN OCULAR DRUG DELIVERY A 441 Topical Systems The isolation of the vitreous caused by the blood-retinal and blood-aqueous barriers creates difficulties for effective drug therapy in all eye diseases (23) Systemic administration... the polymer matrix (15) Microparticles for topical administration are of several types, including polymer -drug complex systems, erodible microspheres, responsive particulates, in situ gelling systems, ion-exchange systems, and nanoparticles (15) B Local Injectable Systems When the vitreous cavity is targeted for drug delivery, topical, systemic, or subconjunctival drug delivery prove unsatisfactory... shorter period of time V BIODEGRADATION AND DRUG RELEASE FROM PARTICULATE SYSTEMS In order to prolong the entrance of drugs into the intraocular structures, a long residence time of the particles in the cul-de-sac and a total desorption Copyright © 2003 Marcel Dekker, Inc Microparticles and Nanoparticles in Ocular Drug Delivery 4 47 of the drug from the particles during that time have to be attained... order to address the above-stated problems, micro- and nanotechnology involving drug- loaded polymer particles has been proposed as an ophthalmic drug delivery technique that may enhance dosage form acceptability while providing sustained release in the ocular milieu (14) Particulate drug delivery consists of systems described as microparticles, nanoparticles, microspheres, nanospheres, microcapsules,... that suggests that cya- Fig 3 Precorneal drainage profile of poly(isobutylcyanoacrylate) nanoparticles: M.W (*) 4, 275 ; (&) 13, 178 ; (~) 72 ,030; (þ) 128,865; (&) 6 07, 439 in g/mol (From Ref 77 .) Copyright © 2003 Marcel Dekker, Inc Microparticles and Nanoparticles in Ocular Drug Delivery 451 noacrylates may have an enhanced bioadhesiveness to inflamed tissues In addition, the ratio of nanoparticles between... polyisobutylcyanoacryate nanocapsules J Pharm Sci., 75 :361 17 Schulman, J A., and Peyman, G A (1993) Intracameral, intravitreal, and retinal drug delivery In: A K Mitra (ed.), Ophthalmic Drug Delivery Systems Marcel Dekker, New York, pp 383–425 18 Kreuter, J., Tauber, U., and Illi, V (1 979 ) Distribution and elimination of poly methyl- 2-1 4-( methacrylate) nanoparticle radioactivity after injection in rat and... rank Copyright © 2003 Marcel Dekker, Inc Microparticles and Nanoparticles in Ocular Drug Delivery 459 order for both the duration and intensity of miosis as II > III ) I, with all differences being significant IX CONCLUSIONS Particulate systems have the potential to become promising systems for ophthalmic drug delivery To date, only one microparticulate ophthalmic prescription product, Betoptic1 S, has... Marchal-Haussler, L., Fessi, H., Devissaguet, J P., Hoffman, M., and Maincent, P (1992) Colloidal drug delivery systems for the eye A comparison of the efficacy of three different polymers: polyisobutylcyanoacrylate, polylactic-coglycolic acid, poly-epsilon-caprolactone Pharm Sci., 2:98 67 Calvo, P., Vila-Jato, J L., and Alonso, M J (19 97) Evaluation of cationic polymer-coated nanocapsules as ocular drug. .. (1993) Liposomes and nanoparticles as ocular drug delivery systems In: Biopharmaceutics of Ocular Drug Delivery CRC Press, Inc., Boca Raton, pp 91–101 Harima, T., Kreuter, J., Speiser, P., Boye, T., Gurny, R., and Kubis, A (1986) Enhancement of miotic response of rabbits with pilocarpine-loaded polybutylcyanoacrylate nanoparticles Int J Pharm., 33:1 87 Kreuter, J (1 978 ) Nanoparticles and nanocapsules—new... time of the drug, enhance the corneal uptake of the drug in unionized form, and decrease the systemic side effects Moreover, the studies show that PECL nanocapsules demonstrate a better effect compared to the PECL nanoparticles for carteolol It was concluded that the drug entrapped in the oily core is more available for corneal absorption 3 H-Labeled hydrocortisone- 1 7- butyrate-21-propionate (3 H-HBP) loaded . above-stated problems, micro- and nanotechnology involving drug- loaded polymer particles has been proposed as an ophthalmic drug delivery technique that may enhance dosage form acceptability. of drug delivery to the eye is topical. Drug- loaded microparticulate systems are suspended in aqueous or nonaqueous medium and instilled typically in the cul-de-sac of the eye, wherefrom drug. with an oil-in-oil emulsion to prepare polylactide-co-glycolide Microparticles and Nanoparticles in Ocular Drug Delivery 443 Copyright © 2003 Marcel Dekker, Inc. microspheres of 5- uorouracil

Định dạng
Số trang	63
Dung lượng	536,82 KB